Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
More articles/Ad
More articles/Ad
More articles
-
Mainland-based Jacobio Pharmaceuticals has kicked off the roadshow for its Hong Kong listing. It is eyeing a valuation of up to HK$10.6bn ($1.37bn). -
The aircraft ABS secondary market experienced a surge in trading activity in November for the first time since the coronavirus outbreak, particularly down the capital structure in the class ‘B’, ‘C’ and equity tranches. Sources say the activity is driven by growing hopes from some funds for a recovery in the sector, met by sellers wanting to clean their books before the year-end.
-
Harbour Biomed has pocketed HK$1.71bn ($220.8m) by pricing its IPO just above the mid point of the marketed range.
-
Medical device maker LifeTech Scientific Corp tapped the Hong Kong market for HK$930m ($120m) in fresh equity on Thursday.
-
Emerging market borrowers seem to be enjoying unfettered access to the capital markets, but many are now questioning whether this Covid-induced debt spree can be sustained in the long run. With fiscal support packages likely to be needed in 2021, investors will be sifting through EM governments to see which will be able to borrow and which will be left behind, writes Mariam Meskin.
-
Competition among public sector borrowers will be more ferocious than ever when 2021 begins, due to supersized borrowing programmes created to deal with the coronavirus pandemic, the European Union’s arrival as a big issuer and a lack of decent funding windows in January, writes Burhan Khadbai.
